280 filings
Page 8 of 14
4
667o9p6wf7y2o99 1wta
30 Mar 21
Oyster Point Pharma / Clare Ozawa ownership change
6:58pm
8-K
93199hs16 0w22
2 Mar 21
U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application
8:17am
SC 13D/A
9fc69jmnu1mq7 syot
1 Mar 21
Oyster Point Pharma / Versant Venture Capital VI ownership change
5:16pm
4
d6yrm2b v5
26 Feb 21
Oyster Point Pharma / Daniel Lochner ownership change
7:50pm
4
arjak1juvt94b 28p
23 Feb 21
Oyster Point Pharma / Jeffrey Nau ownership change
8:13pm
4
yz4o0nwy16akqg
19 Feb 21
Change in insider ownership
5:16pm
4
4u7iv gij
19 Feb 21
Oyster Point Pharma / Clare Ozawa ownership change
5:13pm
8-K
0sbh7ba20dj
18 Feb 21
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:01pm
SC 13G/A
f79 u1iruo2q3yx46q
12 Feb 21
Oyster Point Pharma / RTW INVESTMENTS ownership change
9:30am
SC 13G
gft8 2eeqs
4 Feb 21
Oyster Point Pharma / WELLINGTON MANAGEMENT ownership change
9:57am
4
trhejn66w2u2ws jndt
2 Feb 21
Oyster Point Pharma / John Snisarenko ownership change
6:35pm
4
frtak1 xy8hku
2 Feb 21
Oyster Point Pharma / Jeffrey Nau ownership change
6:33pm
4
ib8djk9psqjlkq1zdq7
2 Feb 21
Oyster Point Pharma / Daniel Lochner ownership change
6:32pm
424B5
ph54kj v8rhtshd
18 Dec 20
Prospectus supplement for primary offering
4:30pm
8-K
v7oom
18 Dec 20
Other Events
7:16am
4
addlu92 rl7yyta
14 Dec 20
Oyster Point Pharma / WILLIAM J PHD LINK ownership change
8:45pm
8-K
kxyz 75vau2ri
2 Dec 20
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021
9:37am
EFFECT
nwjb0k62c0pnc74e7
17 Nov 20
Notice of effectiveness
12:15am
CORRESP
q32egtw0p425gcz92fqy
12 Nov 20
Correspondence with SEC
12:00am